ADCs in the news today also17 Mar 2025 21:25
Schroders Capital Global Innovation Trust plc (the "Company") is pleased to announce that its portfolio company Araris Biotech AG ("Araris"), a Swiss biotechnology company developing next-generation antibody drug conjugates ("ADCs"), on 17 March 2025, has entered into an agreement to be acquired by Taiho Pharmaceutical Co. Ltd., at a purchase price of $400 million upfront, with the potential for additional milestone payments of up to $740 million. Following necessary procedures, the acquisition is expected to be completed in first half of 2025.
Schroders Capital was among the first investors in Araris as part of its CHF 2.5m seed round in 2019. In October 2022, the Company made a CHF 3.0m (Β£2.6m) investment into Araris, to support the further development and advancement of Araris' ADC candidates,